Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Engage Therapeutics is developing Staccato alprazolam for the immediate termination of an active epileptic seizure, or Rapid Epileptic Seizure Termination (REST). The Company anticipates advancing Staccato alprazolam to a Phase 3 registration trial in 2020.

List your booth number for exhibitions, ask us